Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma. Authors' reply-Reference-Cited by-同舟云学术

Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma. Authors' reply

Published:2024-05-06 Issue:11 Volume:59 Page:1465-1466
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Mohr Raphael¹^ORCID,Tacke Frank¹^ORCID,Roderburg Christoph²

Affiliation:

1. Department of Hepatology and Gastroenterology Charité – Universitätsmedizin Berlin Berlin Germany

2. Department of Gastroenterology, Hepatology and Infectious Diseases University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf Düsseldorf Germany

Abstract

LINKED CONTENTThis article is linked to Jost‐Brinkmann et al papers. To view these articles, visit https://doi.org/10.1111/apt.17441 and https://doi.org/10.1111/apt.17985

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.18008

Reference9 articles.

1. Letter: presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma;De Toni EN;Aliment Pharmacol Ther,2024

2. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: results from a German real‐world cohort;Jost‐Brinkmann F;Aliment Pharmacol Ther,2023

3. Immunotherapies for hepatocellular carcinoma;Llovet JM;Nat Rev Clin Oncol,2022

4. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma;Cheng AL;J Hepatol,2022

5. Precision treatment in advanced hepatocellular carcinoma;Yang X;Cancer Cell,2024